Description: <p><b>Auranofin</b> — an orally administered gold(I) coordination complex (gold–phosphine–thiolate “thiosugar” drug) originally approved as a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and widely studied for repurposing as a redox-targeted anticancer and anti-infective agent. It is a small-molecule metallodrug whose pharmacology is typically tracked via blood/plasma <i>gold</i> concentrations because intact auranofin is rapidly transformed and not reliably detected in blood. Standard abbreviation(s): AF (auranofin); primary target shorthand: TrxR/TxNRD (thioredoxin reductase).</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Thioredoxin reductase (TXNRD1/TXNRD2; TrxR) inhibition by gold(I) → thioredoxin system suppression and loss of redox-buffering capacity</li>
<li>ROS and redox stress escalation (secondary to TrxR blockade; often NAC-reversible in models) → apoptosis and other regulated death programs</li>
<li>Mitochondrial dysfunction (Δψm collapse, bioenergetic stress) coupled to redox imbalance</li>
<li>Proteostasis stress (ER stress/UPR; proteasome involvement in selected contexts) → non-apoptotic death phenotypes (model-dependent)</li>
<li>Ferroptosis contribution in subsets of models (lipid peroxidation–dependent; context-dependent)</li>
<li>Radiosensitization / chemosensitization via impaired antioxidant recovery and enhanced oxidative injury (context-dependent)</li>
<li>Stress-response transcription (e.g., NRF2 activation as an adaptive resistance program in some settings; protective in normal cells)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral absorption is incomplete; clinical PK is commonly described as ~25% of the gold content absorbed. Gold is highly protein-bound and exhibits prolonged retention/long terminal half-life, so effective exposure depends strongly on dose and dosing duration. Because “gold levels” are the main measurable surrogate, cross-study comparisons should specify matrix (whole blood vs plasma) and timing (steady-state vs short course).</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many oncology cell studies use ~0.5–5 µM AF. Human short-course data at 6 mg/day for 7 days report plasma gold on the order of ~0.1–0.3 µg/mL (roughly sub-µM to ~1–1.5 µM range when expressed as gold equivalents), meaning lower in-vitro ranges can overlap clinically observed exposure surrogates, while higher µM regimens may exceed typical oral exposures unless higher doses/longer courses or formulation changes are used.</p>
<p><b>Clinical evidence status:</b> Approved for rheumatoid arthritis (historical DMARD use) but <b>oncology use remains investigational</b>. Multiple early-phase repurposing trials exist across hematologic and solid tumors; several completed studies have limited publicly posted outcomes, and there is no established standard-of-care anticancer indication.</p>
<br>
Pathways:<br>
1.Thioredoxin Reductase (TrxR) Inhibition.<br>
- Most widely recognized for potently inhibiting TrxR.<br>
2.Induction of Reactive Oxygen Species (ROS) and Oxidative Stress.<br>
3.MMP depolarization, release of cytochrome c <br>
4.Endoplasmic Reticulum (ER) Stress and Unfolded Protein Response (UPR)<br>
5.Inhibition of Pro-survival Pathways (e.g., NF-κB Signaling)<br>
<br>
-ic50 for cancer typically 1-3uM, normal cell 5-10uM or higher.<br>
-Several studies animal testing antitumor efficacy have used doses in the region of 5–8 mg/kg via intraperitoneal injection or oral administration.<br>
<br>
-Auranofin’s anticancer activity is often linked to its inhibition of thioredoxin reductase, leading to increased oxidative stress.<br>
<h3>Mechanistic axes for Auranofin (Cancer vs Normal)</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>TXNRD1 TXNRD2 Thioredoxin system</td>
<td>↓ (primary)</td>
<td>↓ (primary)</td>
<td>P→R</td>
<td>Collapse of thioredoxin redox buffering</td>
<td>Core, proximal target of AF; downstream effects track with redox reserve and compensatory antioxidant capacity rather than tumor lineage alone.</td>
</tr>
<tr>
<td>2</td>
<td>ROS redox stress</td>
<td>↑ (often primary downstream)</td>
<td>↑ (dose-dependent)</td>
<td>P→R</td>
<td>Oxidative injury signaling and death pathway engagement</td>
<td>Frequently reversible with thiol antioxidants (e.g., NAC) in models, supporting causality; magnitude depends on baseline redox fragility.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondria bioenergetics</td>
<td>Δψm ↓, ATP stress ↑ (context-dependent)</td>
<td>Δψm ↓ (dose-dependent)</td>
<td>R</td>
<td>Energetic crisis and intrinsic death susceptibility</td>
<td>Often coupled to redox imbalance; can amplify apoptosis/regulated necrosis depending on cellular checkpoints.</td>
</tr>
<tr>
<td>4</td>
<td>Proteostasis ER stress UPR</td>
<td>↑ (model-dependent)</td>
<td>↔/↑ (high exposure only)</td>
<td>R→G</td>
<td>Protein-folding overload and non-apoptotic death phenotypes</td>
<td>Some reports implicate proteasome participation and paraptosis-like outcomes; not universal across tumor types.</td>
</tr>
<tr>
<td>5</td>
<td>NRF2 antioxidant response</td>
<td>↑ (adaptive; resistance role)</td>
<td>↑ (cytoprotective)</td>
<td>R→G</td>
<td>Transcriptional compensation to redox stress</td>
<td>NRF2 induction can blunt AF efficacy in tumors yet protect normal tissues; net effect is (context-dependent).</td>
</tr>
<tr>
<td>6</td>
<td>Ferroptosis lipid peroxidation</td>
<td>↑ (model-dependent)</td>
<td>↔/↑ (stress-prone contexts)</td>
<td>R→G</td>
<td>Regulated death component in subsets</td>
<td>Most consistent when AF-driven redox stress converges on lipid ROS handling; requires model-specific validation.</td>
</tr>
<tr>
<td>7</td>
<td>Radiosensitization chemosensitization</td>
<td>↑ sensitivity (context-dependent)</td>
<td>↑ toxicity risk (context-dependent)</td>
<td>R→G</td>
<td>Impaired antioxidant recovery increases treatment injury</td>
<td>Mechanistically coherent with TrxR blockade; best supported where oxidative damage markers and combination indices are shown.</td>
</tr>
<tr>
<td>8</td>
<td>Ca²⁺ stress coupling</td>
<td>↑/↔ (secondary)</td>
<td>↑/↔ (secondary)</td>
<td>R</td>
<td>Amplifies ER mitochondrial death signaling</td>
<td>Usually downstream of redox + organelle perturbation; include when Ca²⁺-dependent apoptosis/ER stress is explicitly demonstrated.</td>
</tr>
<tr>
<td>9</td>
<td>Glycolysis ATP production</td>
<td>↓ (context-dependent)</td>
<td>↔/↓ (high exposure only)</td>
<td>R</td>
<td>Metabolic stress that can reduce proliferative fitness</td>
<td>Reported in some models; may be secondary to mitochondrial/redox disruption rather than a primary binding target.</td>
</tr>
<tr>
<td>10</td>
<td>HIF-1α hypoxia programs</td>
<td>↔ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Context marker rather than core axis</td>
<td>Evaluate case-by-case; AF’s primary leverage is redox enzyme inhibition, with HIF effects emerging indirectly in some systems.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>↔</td>
<td>—</td>
<td>Exposure, tolerability, and selectivity limit window</td>
<td>Oral absorption is incomplete and gold is long-retained/protein-bound; many oncology studies rely on µM in-vitro dosing that may exceed typical oral exposure surrogates. Oncology trials exist but anticancer efficacy is not established as standard-of-care.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min | R: 30 min–3 hr | G: >3 hr</p>